Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) EBITDA (2016 - 2025)

CorMedix's EBITDA history spans 14 years, with the latest figure at -$84994.0 for Q4 2025.

  • For Q4 2025, EBITDA fell 4375.35% year-over-year to -$84994.0; the TTM value through Dec 2025 reached -$88000.0, down 2833.33%, while the annual FY2025 figure was -$88000.0, 2833.33% down from the prior year.
  • EBITDA for Q4 2025 was -$84994.0 at CorMedix, down from $8205.0 in the prior quarter.
  • Across five years, EBITDA topped out at $8205.0 in Q3 2025 and bottomed at -$11.3 million in Q2 2023.
  • The 5-year median for EBITDA is -$6.8 million (2022), against an average of -$4.8 million.
  • The largest YoY upside for EBITDA was 142.11% in 2025 against a maximum downside of 4375.35% in 2025.
  • A 5-year view of EBITDA shows it stood at -$7.8 million in 2021, then decreased by 4.78% to -$8.2 million in 2022, then dropped by 28.09% to -$10.5 million in 2023, then skyrocketed by 100.02% to $1988.0 in 2024, then tumbled by 4375.35% to -$84994.0 in 2025.
  • Per Business Quant, the three most recent readings for CRMD's EBITDA are -$84994.0 (Q4 2025), $8205.0 (Q3 2025), and -$5121.0 (Q2 2025).